利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.012 秒)

    IMPROVED IMAGING OF IMMUNOMAGNETICALLY ENRICHED RARE CELLS
    1.
    发明公开
    IMPROVED IMAGING OF IMMUNOMAGNETICALLY ENRICHED RARE CELLS 有权
    磁免疫细胞的改进的成像富硒RARE

    公开(公告)号：EP2288919A2

    公开(公告)日：2011-03-02

    申请号：EP09751377.4

    申请日：2009-05-19

    申请人： Veridex, LLC

    发明人： SCHOLTENS, Tycho, M. ,  SCHREUDER, Frederik ,  GREVE, Jan ,  TIBBE, Arjan ,  TERSTAPPEN, Leon, W., M., M.

    IPC分类号： G01N33/53

    CPC分类号： G01N33/54326

    摘要： A method for removing excess unbound ferrofluid and imaging immunomagnetically enriched circulating tumor cells is provided. A vessels having a preformed grooves in the viewing surface is optimally designed for cell alignment and imaging. After separating the unbound particles by centrifugation, an externally-applied force is applied to transport magnetically responsive particle-CTC complex toward the transparent collection wall. The grooved inner surface of the viewing face of the chamber provide uniform distribution of the particles for easy imaging. The invention is also useful in conducting quantitative analysis and sample preparation in conjunction with automated cell enumeration techniques as in quantitative analysis of CTC in disease.

    CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
    3.
    发明授权
    CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS 有权
    循环肿瘤细胞（CTC的）：疾病进展时间，生存和对治疗反应的早期评价转移癌患者

    公开(公告)号：EP1597353B1

    公开(公告)日：2010-11-24

    申请号：EP04715133.7

    申请日：2004-02-26

    申请人： Veridex, LLC

    发明人： ALLARD, Jeffrey, W. ,  CRISTOFANILLI, Massimo ,  TERSTAPPEN, Leon, W., M., M.

    IPC分类号： C12N1/00 ,  G01N33/48 ,  G01N33/53 ,  G01N33/574

    CPC分类号： G01N33/574 ,  G01N33/54326 ,  G01N2800/52

    摘要： A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.